LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Amgen Inc

Închisă

SectorSănătate

290.17 1.13

Rezumat

Modificarea prețului

24h

Curent

Minim

289.48

Maxim

290.72

Indicatori cheie

By Trading Economics

Venit

1.1B

1.7B

Vânzări

-937M

8.1B

P/E

Medie Sector

26.32

51.198

EPS

4.9

Randament dividend

3.3

Marjă de profit

21.23

Angajați

28,000

EBITDA

-1.7B

1.2B

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+12.35% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

3.30%

2.40%

Următoarele câștiguri

5 aug. 2025

Data viitoare de dividende

5 sept. 2025

Următoarea dată ex-dividende

15 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-3B

155B

Deschiderea anterioară

289.04

Închiderea anterioară

290.17

Sentimentul știrilor

By Acuity

39%

61%

126 / 380 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Amgen Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

1 mai 2025, 20:17 UTC

Câștiguri

Amgen 1Q Revenue Up 9% as Many Products Deliver Double-Digit Sales Growth

28 mai 2025, 18:09 UTC

Câștiguri

Heart Disease Could Be a Goner When These New -2-

28 mai 2025, 18:09 UTC

Câștiguri

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

19 mai 2025, 16:13 UTC

Achiziții, Fuziuni, Preluări

Regeneron Is Buying 23andMe. The Deal Is a Head Scratcher. -- Barrons.com

1 mai 2025, 20:01 UTC

Câștiguri

Amgen: FY25 Share Repurchases Not to Exceed $500M

1 mai 2025, 20:01 UTC

Câștiguri

Amgen: Guidance Includes Estimated Impact of Implemented Tariffs>AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen Sees FY25 Capital Expenditures About $2.3B

1 mai 2025, 20:01 UTC

Câștiguri

Amgen: Guidance Doesn't Account for Any Tariffs That Could Be Implemented in Future, Including Sector-specific Tariffs

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q Repatha Sales $656M >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q EVENITY Sales $442M >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q Worldwide Neulasta Sales $129M >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen Sees FY25 Adj EPS $20-Adj EPS $21.20 >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q Net $1.73B >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen Sees FY25 EPS $12.21-EPS $13.46 >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q Adj EPS $4.90 >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen Sees FY25 Rev $34.3B-$35.7B >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q Worldwide XGEVA Sales $566M >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q Worldwide Prolia Sales $1.1B >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q EPS $3.20 >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q Worldwide Enbrel Sales $510M >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q Rev $8.15B >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q Worldwide Enbrel Sales $510M >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q Rev $8.1B >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q Net $1.73B >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q Worldwide Neulasta Sales $129M >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen Sees FY EPS $12.21-EPS $13.46 >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q Worldwide Prolia Sales $1.1B >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q Worldwide XGEVA Sales $566M >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen 1Q EPS $3.20 >AMGN

1 mai 2025, 20:01 UTC

Câștiguri

Amgen Sees FY Adj EPS $20.00-Adj EPS $21.20 >AMGN

Comparație

Modificare preț

Amgen Inc Așteptări

Obiectiv de preț

By TipRanks

12.35% sus

Prognoză pe 12 luni

Medie 326.18 USD  12.35%

Maxim 400 USD

Minim 252 USD

În baza a 22 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAmgen Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

22 ratings

11

Cumpărare

10

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

270.44 / 276.44Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

126 / 380 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.